ProMIS Neurosciences showcases preclinical data at AAIC 2023

ProMIS Neurosciences presented preclinical data further supporting the potential therapeutic advantage of lead candidate for AD, PMN310, a humanized IgG1 antibody directed toward toxic amyloid-beta oligomers. Additionally, the Company presented preclinical mouse studies that further characterize a computationally-derived AD vaccine directed at AbetaO. The data were presented in posters on July 16, 2023, at the Alzheimer’s Association International Conference, AAIC, 2023 in Amsterdam, Netherlands. Details of the poster presentation are as follows: PMN310 for the Potential Treatment of Alzheimer’s Disease. Title: “Selective targeting and protection against toxic amyloid-beta oligomers by PMN310, a monoclonal antibody rationally designed for greater therapeutic potency in Alzheimer’s disease.” In preclinical studies, the binding selectivity of PMN310 was compared to that of other Abeta-directed antibodies using surface plasmon resonance. The results demonstrated that PMN310 was able to selectively bind to toxic AbetaO in AD brain extract and was less impacted by monomer competition than other Abeta-directed antibodies except ACU193, which was equivalent to PMN310. Additionally, of all antibodies tested including biosimilars for ACU193 and PRX012, only PMN310 and solanezumab did not bind to plaque, potentially reducing the incidence of Abeta-related imaging abnormalities associated with plaque-binding antibodies. Vaccine Candidate for Potential Prevention of Alzheimer’s Disease. Title: “Rational design of a vaccine for Alzheimer’s disease using a computationally-derived conformational epitope to selectively target toxic amyloid-beta oligomers.” The preclinical evaluation of ProMIS’ vaccine candidate consisting of an AbetaO conformational B cell peptide epitope conjugated to a carrier protein to provide T cell help, elicited a robust and sustained antibody response with either alum or QS-21 as adjuvants approved for human use. The serum antibodies were selective for AbetaO with no detectable binding to monomers or plaque, potentially reducing the risk of ARIA. These results support ProMIS’s approach to designing a vaccine for AD prevention with the potential for sustained anti-disease activity and ease of use with fewer doses compared to chronic antibody treatment.